Literature DB >> 10729891

Impact of Vertical Banded Gastroplasty on Respiratory Insufficiency of Severe Obesity.

.   

Abstract

BACKGROUND: Respiratory insufficiency associated with morbid obesity can include sleep apnea syndrome (SAS), obesity hypoventilation syndrome (OHS), or a combination of both. The aim of our study was to determine the safety and effectiveness of vertical banded gastroplasty (VBG) in the treatment of severely obese patients with respiratory insufficiency.
METHODS: From 1983 to 1994, 35 patients (25 males, ten females) who met the criteria for either SAS and OHS (1 9 patients) or SAS alone (1 6 patients) underwent VBG.
RESULTS: Six patients (17%) died of subsequent pulmonary-cardiac disease despite significant weight loss. Need for nasal continuous positive airway pressure (CPAP) decreased after VBG from 68% of patients preoperatively to 22% postoperatively. Of the ten patients with sleep studies, the apnea/hyponea index decreased from 45 +/- 11 events per h preoperatively to 12 +/- 6 events per h postoperatively, while per cent ideal body weight (%IBW) also decreased (pre-VBG: 268 +/- 12, post-VBG: 204 +/- 12). Of the seven patients with arterial blood gases, PaCO&inf2; decreased from 55 +/- 4 torr preoperatively to 41 +/- 3 torr postoperatively, and PaO&inf2; increased from 50 +/- 4 torr preoperatively to 73 +/- 6 torr postoperatively, while %IBW decreased (pre-VBG: 263 +/- 16, post-VBG: 193 +/- 14).
CONCLUSION: Respiratory insufficiency is a life-threatening complication of morbid obesity. In morbidly obese patients with respiratory insufficiency, VBG offers improvement in both SAS and OHS. Respiratory insufficiency due to obesity should be considered a strong indication for VBG.

Entities:  

Year:  1996        PMID: 10729891     DOI: 10.1381/096089296765556322

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  7 in total

1.  Practice patterns in high-risk bariatric venous thromboembolism prophylaxis.

Authors:  Howard I Pryor; Adam Singleton; Elissa Lin; Paul Lin; Khashayar Vaziri
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

2.  New insights on obstructive sleep apnea syndrome and related comorbidities in morbidly obese patients submitted to bariatric surgery.

Authors:  Pilar Sanchis; Carla Frances; Joana Nicolau; Rosmeri Rivera; Regina Fortuny; Xavier Julian; Salvador Pascual; Luis A Gomez; Irene Rodriguez; Josefina Olivares; Luisa Ayala; Luis Masmiquel
Journal:  Obes Surg       Date:  2014-11       Impact factor: 4.129

3.  Obesity Hypoventilation Syndrome.

Authors:  Safal Shetty; Sairam Parthasarathy
Journal:  Curr Pulmonol Rep       Date:  2015-03-01

4.  Improvement of associated respiratory problems in morbidly obese patients after open Roux-en-Y gastric bypass.

Authors:  C Martí-Valeri; A Sabaté; C Masdevall; A Dalmau
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

Review 5.  Assessment and management of patients with obesity hypoventilation syndrome.

Authors:  Babak Mokhlesi; Meir H Kryger; Ronald R Grunstein
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

6.  Baseline of visceral fat area and decreased body weight correlate with improved pulmonary function after Roux-en-Y gastric bypass in Chinese obese patients with BMI 28-35 kg/m² and type 2 diabetes: a 6-month follow-up.

Authors:  Yinfang Tu; Haoyong Yu; Yuqian Bao; Pin Zhang; Jianzhong Di; Xiaodong Han; Weiping Jia
Journal:  BMC Endocr Disord       Date:  2015-06-09       Impact factor: 2.763

7.  Evaluation and Management of Obesity Hypoventilation Syndrome. An Official American Thoracic Society Clinical Practice Guideline.

Authors:  Babak Mokhlesi; Juan Fernando Masa; Jan L Brozek; Indira Gurubhagavatula; Patrick B Murphy; Amanda J Piper; Aiman Tulaimat; Majid Afshar; Jay S Balachandran; Raed A Dweik; Ronald R Grunstein; Nicholas Hart; Roop Kaw; Geraldo Lorenzi-Filho; Sushmita Pamidi; Bhakti K Patel; Susheel P Patil; Jean Louis Pépin; Israa Soghier; Maximiliano Tamae Kakazu; Mihaela Teodorescu
Journal:  Am J Respir Crit Care Med       Date:  2019-08-01       Impact factor: 21.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.